Insider Purchases: Inside the Buy

Tag: Funanc1alBiotech

Digital illustration of biotech company MaxCyte (MXCT): glowing cell zapped by electricity ⚡ with executives buying shares 🛒💉, symbolizing insider buys vs. cash burn.

MaxCyte (MXCT) — Insiders Load Up While Cash Burns

MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?

 

Read entire article

Tags: BiotechStocks, CashBurn, CellTherapy, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, DIrector Buying, Director Insider Buying, Funanc1al, Funanc1al Stocks to Watch, Funanc1alBiotech, Funanc1alEdge, Funanc1alHealth, Funanc1alInsiders, Funanc1alInsiderSeries, Funanc1alInsights, Funanc1alInvesting, Funanc1alStocks, HighRiskHighReward, InsiderBuying, InstitutionalOwnership, MaxCyte, MXCT, SpeculativePlays
Illustration of a giant Eli Lilly pill capsule spilling cash, rising stock charts, and drug bottles, symbolizing blockbuster earnings, insider buying, and growth momentum.

Elite Buys Ely: Should You Buy Lilly’s Stock Too?

Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?

Read entire article

Tags: Biopharma, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Eli Lilly, Eli Lilly vs Novo Nordisk, Funanc1al Insider Series, Funanc1al Stocks to Watch, Funanc1alBiotech, Funanc1alEdge, Funanc1alFun, Funanc1alHumor, Funanc1alInsiderSeries, Funanc1alInsights, Funanc1alInvesting, Funanc1alPharma, Funanc1alStocks, Healthcare Stocks, High Growth Stocks, Insider Buying, Institutional Ownership, LLY, Mounjaro, Obesity Drugs, Orforglipron, Pharmaceutical Earnings, Zepbound
Bezuclastinib vial on biotech lab bench, with clinical trial data and stock chart rising in background—symbolizing COGT’s potential breakthrough

Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib

Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥

Read entire article

Tags: Bezuclastinib, Biotech Stocks, Clinical Trials, COGT, Cole Pinnow, Fairmount Funds, Funanc1al Insider Series, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHealth, Funanc1alHumor, Funanc1alInsiders, Funanc1alInsiderSeries, Funanc1alInvesting, Funanc1alPharma, Funanc1alStocks, GIST, Insider Buying, Speculative Plays, Systemic Mastocytosis